Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03504410
Recruitment Status : Recruiting
First Posted : April 20, 2018
Last Update Posted : May 9, 2019
Sponsor:
Information provided by (Responsible Party):
Rafael Pharmaceuticals Inc.

Brief Summary:
A Phase III study to evaluate the safety and efficacy of CPI-613 in combination with High Dose Cytarabine and Mitoxantrone in comparison with high dose Cytarabine and Mitoxantrone in older patients with relapsed/refractory Acute Myeloid Leukemia. CPI-613 targets the altered energy metabolism and processes for production of ATP and essential bio-intermediates unique to and characteristic of most cancer cell types. The addition of CPI-613 to high dose cytarabine and mitoxantrone (CHAM) will improve the complete remission (CR) rate in patients 60 years or older with relapsed or refractory AML when compared to HAM alone.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory Acute Myeloid Leukemia Drug: CPI-613 + High Dose Cytarabine and Mitoxantrone Drug: High Dose Cytarabine and Mitoxantrone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 Years) With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Actual Study Start Date : November 12, 2018
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : March 2023


Arm Intervention/treatment
Experimental: CPI-613 + HD Cytarabine and Mitoxantrone

CPI-613 + High Dose Cytarabine and Mitoxantrone

CPI-613 at 2,000 mg/m2/day from day 1 to 5.

Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine.

Drug: CPI-613 + High Dose Cytarabine and Mitoxantrone
CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
Other Name: CPI-613, CHAM

Active Comparator: HD Cytarabine and Mitoxantrone

High Dose Cytarabine and Mitoxantrone

Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.

Drug: High Dose Cytarabine and Mitoxantrone
Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
Other Name: HAM




Primary Outcome Measures :
  1. Complete Remission (CR) [ Time Frame: 8 months ]
    Complete disappearance of all clinical evidence of disease


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 12 months ]
    the duration from the date of randomization to the date of death from any cause

  2. CRh [ Time Frame: 12 months ]
    CR with partial hematological recovery (CRh)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  1. Patient has provided an informed consent prior to initiation of any study specific activities/procedures.
  2. Males and females age ≥ 60 years must have histologically documented AML that is relapsed from, or refractory to, prior standard therapies.
  3. Refractory is defined as failure to achieve CR or CRi following:

    1. Two standard dose Cytarabine based induction cycles or one HiDAC based cycle, or
    2. Failure to respond to one cycle of either standard dose or HiDAC (defined as no decrease in marrow blast percentage from diagnosis on Day 14 marrow), or
    3. No response after at least 3 cycles of a hypomethylating agent (azacytidine or decitabine).
  4. Relapse is defined as development of recurrent AML (as described by Döhner et al, 2010)6 after CR or CRi has been achieved with a prior chemotherapy or after disease progression on a hypomethylating agent.
  5. ECOG PS 0-2.
  6. Expected survival >3 months.
  7. Women of child-bearing potential (i.e. women who are pre-menopausal or < 2 years post menopausal or not surgically sterile) must use 2 effective contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive, injectable or implantable agent/device or double barrier device (diaphragm + spermicide) during and for 6 months after the last administered dose of CHAM or HAM therapy, and must have a negative serum pregnancy test within 1 week prior to treatment initiation (Note: pregnant patients are excluded because the effects of CPI 613 on a fetus are unknown).
  8. Fertile men must practice effective contraceptive methods (condom + spermicide) during the study period and up to 6 months after completion of the study screening, unless documentation of infertility exists.
  9. Good state of mental health, ability to understand and willingness to sign the informed consent form (ICF).
  10. No radiotherapy, treatment with cytotoxic chemotherapy, treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI 613. Hydroxyurea and oral tyrosine kinase (FLT3) or Isocitrate Dehydrogenase 1 and 2 (IDH1/2) inhibitors being used with Grade ≤ 2 toxicity can be taken until the day prior to starting study therapy. Previous exposure to a hypomethylating agent either alone or in combination with Venetoclax is allowed. Patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities with the exception of alopecia (returned to baseline status as noted before most recent treatment). Patients with persisting, non-hematologic, non-infectious toxicities from prior treatment Grade ≤ 2 are eligible but must be documented as such.
  11. Laboratory values ≤ 2 weeks before dosing must be:

    • Adequate hepatic function (aspartate aminotransferase/serum glutamic-oxaloacetic transaminase [AST/SGOT] ≤ 5 x upper limit of normal [ULN], alanine aminotransferase/serum glutamic oxaloacetic transaminase [ALT/SGPT] ≤ 5 × ULN, bilirubin ≤ 1.5 × ULN).
    • Adequate renal function (serum creatinine clearance ≥ 60 mL/min per CockCroft Gault formula).
    • Adequate coagulation (International Normalized Ratio [INR] must be < 1.7 unless on vitamin k antagonist anticoagulation).
  12. Left Ventricular Ejection Fraction (LVEF) by Transthoracic Echocardiogram (TTE), Multigated Acquisition Scan (MUGA) or cardiac Magnetic Resonance Imaging (MRI), sufficient to safely administer mitoxantrone. Subjects must have an LVEF ≥ 45%.
  13. No marked baseline prolongation of QT/QTc interval (repeated exhibition of a QTc interval > 450 ms for male and > 470 ms for female patients).
  14. No history of additional risk factors for torsade de pointes (e.g. clinically significant heart failure, hypokalemia, immediate family history of Long QT Syndrome).

EXCLUSION CRITERIA:

  1. Patients who have received previous cytotoxic chemotherapy treatment for their relapsed or refractory AML. Previous treatment with hypomethylating agents (decitabine or azacytidine) either alone or in combination with Venetoclax is allowed. Targeted therapies including FLT3 or IDH1/2 inhibitors or Hydrea are allowed. Targeted therapies and Hydrea may be taken until the day prior to starting CHAM or HAM therapy.
  2. History or evidence of any other clinically significant disorder, condition or disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion.
  3. Patients with active Central Nervous System (CNS) involvement (leukemic infiltration, blast in the spinal fluid).
  4. Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g. active peptic ulcer disease).
  5. Female patients who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 months after the last dose of CHAM or HAM therapy (the teratogenic potential of CPI-613 is unknown). Female patients of childbearing potential with a positive pregnancy test assessed by a serum pregnancy test at Screening.
  6. Female patients of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for 6 months after completion of CHAM or HAM therapy for AML.
  7. Male patients with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for 6 months after completion of CHAM or HAM therapy.
  8. Male patients unwilling to abstain from donating sperm during treatment and for 6 months after completion of CHAM or HAM therapy with potential highest teratogenic risk.
  9. Patient has known sensitivity to any of the CHAM or HAM medications to be administered during dosing.
  10. Life expectancy less than 3 months.
  11. Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
  12. Unwilling or unable to follow protocol requirements.
  13. Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly).
  14. Patients with any amount of clinically significant pericardial effusion that requires drainage.
  15. Evidence of ongoing, uncontrolled bacterial, viral or fungal infection.
  16. Patients with known human immunodeficiency virus infection.
  17. History of other malignancy within the past 5 years, with the following exception(s):

    1. Malignancy treated with curative intent and with no known active disease present for ≥ 5 years before enrolment and felt to be at low risk for recurrence by the treating physician.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of recurrent or residual disease.
    3. Adequately treated cervical carcinoma in situ without evidence of disease.
    4. Prostate cancer Stage 1.
  18. Patients receiving any other standard or investigational treatment for AML, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment (the use of Hydrea and/or oral tyrosine kinase inhibitors FLT3 or IDH 1/2 inhibitors is allowed until the day prior to starting CHAM or HAM therapy). Previous exposure to a hypomethylating agent either alone or in combination with Venetoclax is allowed.
  19. Patients who have received immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment.
  20. Requirement for immediate palliative treatment of any kind including minor surgery.
  21. Patients who have received a chemotherapy regimen with autologous stem cell support (bone marrow transplantation) within 6 months of starting CHAM or HAM therapy.
  22. Patients who have had allogenic bone marrow transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03504410


Contacts
Layout table for location contacts
Contact: Sanjeev Luther 585-978-1351 sanjeev.luther@rafaelpharma.com

Locations
Layout table for location information
United States, California
Chao Family Comprehensive Cancer Center (University of California Irvine) Recruiting
Orange, California, United States, 92868
Principal Investigator: Deepa Jeyakumar, MD         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Richard A Larson, MD         
United States, North Carolina
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Principal Investigator: Bayard L Powell, MD         
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Principal Investigator: Zartash Gul, MD         
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Principal Investigator: Aziz Nazha, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Rachel Cook, MD         
Sponsors and Collaborators
Rafael Pharmaceuticals Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jorge Eduardo Cortes, MD M.D. Anderson Cancer Center

Layout table for additonal information
Responsible Party: Rafael Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03504410     History of Changes
Other Study ID Numbers: AML003
First Posted: April 20, 2018    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Mitoxantrone
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors